Commissioning statements

APC commissioning statement decision making criteria September 2013

Commissioning Statement Process – updated August 2018

The following commissioning statements have been agreed by the members of the South West Yorkshire Area Prescribing Committee:

 

DRUG/TREATMENTCOMMISSIONING
STATEMENT
APC APPROVED DATEREVIEW DATEAPC Date or other
(n) = new
(a) = amendment
Antioxident Vitamins in Age related Macular Degeneration (AMD)NICE guidance
Not routinely commissioned in Primary Care
Botulinum Toxin Type ABotulinum16th January 2015Awaiting RMOC decision
Brimonidine gel (for treatment of facial erythema of rosacea in adults)Brimonidine27th September 2019September 202127th September 2019 (a)
Dapoxetinedapoxetine November 2016January 2020
Flash Glucose MonitoringWY&H Flash Glucose 1st May 2019May 2022
Glucosamine or Chondroitin productsNICE guidance
Not routinely commissioned in Primary Care
Herbal medicines and health supplementsNICE guidance
Not routinely commissioned in Primary Care
Homeopathic MedicinesNICE guidance
Not routinely commissioned in Primary Care
Hyaluronic Acid and its derivatives (injectables) - for the treatment of osteoarthritis and other joint conditions)Hyaluronic1st September 2018September 2021
Hydrocortisone tabletshydrocortisone November 2019November 202227th November 2019 (a)
Licensed E-cigarettese-cigarettes 10th October 2017October 2020
Linaclotide TabletsNICE guidance
Linaclotide
Liothyronine ArmourWY&H Liothyronine Commissioning Statement20th May 2019April 2021
Liraglutide (for Obesity)Liraglutide 10th October 2017October 2020
Medicines for dental conditions on FP10 prescriptionNICE guidance
Not routinely commissioned in Primary Care
Phosphodiesterase type-5 inhibitors (for treatment of penile rehabilitation post radical prostatectomy or radiotherapy)Replaced by Sildenafil1st January 2019March 2022
Rituximab for RA without methotrexateRituximab 23rd May 2017April 2020
SildenafilSildenafil1st January 2019March 2022
Silicone scar gels and sheets - for healing skin (not open wounds) to reduce redness and try to minimise hypertrophic or keloid scarsSilicone November 2019November 2022
Silk GarmentsNICE guidance
Not routinely commissioned in Primary Care
Tocilizumab SC (for Treatment of Rheumatoid Arthritis/Active Systemic Juvenile Idiopathic Arthritis)Tocilizumab2nd October 2014March 2022
Trans-anal Irrigation SystemsTrans-anal 11th September 2017May 2021
Travel MedicinesNICE guidance
Not routinely commissioned in Primary Care

 

Flash Glucose Monitoring – Updated July 2019

We have been working with diabetes specialists in West Yorkshire and Harrogate to update our policies on flash glucose monitoring, following the publication of new guidance from NHS England, and to agree a single policy for all nine clinical commissioning groups.

A Flash Glucose commissioning policy for West Yorkshire and Harrogate has been approved and will start to implement the NHS England guidance regarding “Flash Glucose Monitoring: National Arrangements for Funding of Relevant Diabetes Patients.”  The Diabetes Specialist Teams in local areas will be responsible for assessing whether patients meet the criteria in this guidance, starting flash glucose monitoring and ongoing review.  The continued  supply of the flash glucose monitoring sensors will transfer to the patients GP practice.

There are available adult and paediatric patient agreement forms for Flash Glucose Monitoring here.

 

Items which should not routinely be prescribed in Primary Care: Guidance for CCGs

Following the publication of the above NHSE guidance to CCGs; the SWYAPC CCGs intend to commission in line with the guidance and align the Commissioning Statements.

The SWYAPC have produced a letter to inform Community Pharmacies in Bradford, Calderdale, Kirklees and Wakefield of the local plans regarding the NHSE guidance.